These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

309 related articles for article (PubMed ID: 25531356)

  • 1. New drugs on the horizon for IBD.
    Sands BE
    Dig Dis; 2014; 32 Suppl 1():74-81. PubMed ID: 25531356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of drugs to target interactions between leukocytes and endothelial cells and treatment algorithms for inflammatory bowel diseases.
    Danese S; Panés J
    Gastroenterology; 2014 Nov; 147(5):981-9. PubMed ID: 25220794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel treatment options for inflammatory bowel disease: targeting alpha 4 integrin.
    Lanzarotto F; Carpani M; Chaudhary R; Ghosh S
    Drugs; 2006; 66(9):1179-89. PubMed ID: 16827596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel therapeutic targets for inflammatory bowel disease.
    Argollo M; Fiorino G; Hindryckx P; Peyrin-Biroulet L; Danese S
    J Autoimmun; 2017 Dec; 85():103-116. PubMed ID: 28711286
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leukocyte Anti-Trafficking Strategies: Current Status and Future Directions.
    Sands BE
    Dig Dis; 2017; 35(1-2):13-20. PubMed ID: 28147349
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging Treatment Options in Inflammatory Bowel Disease: Janus Kinases, Stem Cells, and More.
    Misselwitz B; Juillerat P; Sulz MC; Siegmund B; Brand S;
    Digestion; 2020; 101 Suppl 1():69-82. PubMed ID: 32570252
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biologic therapies against inflammatory bowel disease: a dysregulated immune system and the cross talk with gastrointestinal mucosa hold the key.
    Dharmani P; Chadee K
    Curr Mol Pharmacol; 2008 Nov; 1(3):195-212. PubMed ID: 20021434
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Emerging immunological targets in inflammatory bowel disease.
    Monteleone G; Pallone F; MacDonald TT
    Curr Opin Pharmacol; 2011 Dec; 11(6):640-5. PubMed ID: 22000933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel strategies for the treatment of inflammatory bowel disease: Selective inhibition of cytokines and adhesion molecules.
    Nakamura K; Honda K; Mizutani T; Akiho H; Harada N
    World J Gastroenterol; 2006 Aug; 12(29):4628-35. PubMed ID: 16937430
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Next-Generation Therapeutics for IBD.
    Löwenberg M; D'Haens G
    Curr Gastroenterol Rep; 2015 Jun; 17(6):21. PubMed ID: 26031830
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease--an update.
    Cesarini M; Fiorino G
    Expert Rev Clin Immunol; 2013 Apr; 9(4):301-6. PubMed ID: 23557266
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Involvement of JAK/STAT signaling in the pathogenesis of inflammatory bowel disease.
    Coskun M; Salem M; Pedersen J; Nielsen OH
    Pharmacol Res; 2013 Oct; 76():1-8. PubMed ID: 23827161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-integrin therapy for inflammatory bowel disease.
    Park SC; Jeen YT
    World J Gastroenterol; 2018 May; 24(17):1868-1880. PubMed ID: 29740202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New drug therapies on the horizon for IBD.
    Perrier C; Rutgeerts P
    Dig Dis; 2012; 30 Suppl 1():100-5. PubMed ID: 23075877
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Physiological basis for novel drug therapies used to treat the inflammatory bowel diseases. I. Immunology and therapeutic potential of antiadhesion molecule therapy in inflammatory bowel disease.
    Van Assche G; Rutgeerts P
    Am J Physiol Gastrointest Liver Physiol; 2005 Feb; 288(2):G169-74. PubMed ID: 15647604
    [TBL] [Abstract][Full Text] [Related]  

  • 16. JAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokines.
    Danese S; Grisham M; Hodge J; Telliez JB
    Am J Physiol Gastrointest Liver Physiol; 2016 Feb; 310(3):G155-62. PubMed ID: 26608188
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inflammatory bowel disease therapy: blockade of cytokines and cytokine signaling pathways.
    Yamamoto-Furusho JK
    Curr Opin Gastroenterol; 2018 Jul; 34(4):187-193. PubMed ID: 29846261
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New treatment options for inflammatory bowel diseases.
    Verstockt B; Ferrante M; Vermeire S; Van Assche G
    J Gastroenterol; 2018 May; 53(5):585-590. PubMed ID: 29556726
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory pathways of importance for management of inflammatory bowel disease.
    Pedersen J; Coskun M; Soendergaard C; Salem M; Nielsen OH
    World J Gastroenterol; 2014 Jan; 20(1):64-77. PubMed ID: 24415859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Immunotherapy of inflammatory bowel diseases].
    Wichan P; Chojnacki J; Wojtuń S
    Pol Merkur Lekarski; 2004; 17 Suppl 1():40-3. PubMed ID: 15603345
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.